The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant candida albicans

Nathan P. Wiederhold, Laura K. Najvar, Annette W. Fothergill, Dora I. McCarthy, Rosie Bocanegra, Marcos Olivo, William R. Kirkpatrick, Michael P. Everson, Frederick P. Duncanson, Thomas F. Pattersona

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandinresistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.

Original languageEnglish (US)
Pages (from-to)690-692
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant candida albicans'. Together they form a unique fingerprint.

  • Cite this

    Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., McCarthy, D. I., Bocanegra, R., Olivo, M., Kirkpatrick, W. R., Everson, M. P., Duncanson, F. P., & Pattersona, T. F. (2015). The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant candida albicans. Antimicrobial agents and chemotherapy, 59(1), 690-692. https://doi.org/10.1128/AAC.03944-14